Peterson L S, Nelson A M, Su W P
Division of Rheumatology and Internal Medicine, Mayo Clinic Rochester, MN 55905, USA.
Mayo Clin Proc. 1995 Nov;70(11):1068-76. doi: 10.4065/70.11.1068.
To classify and describe morphea (localized scleroderma).
A review of morphea and its subtypes is presented.
The current classification of morphea is incomplete and confusing. As knowledge of the spectrum of disease continues to evolve, the controversy and confusing nature of its multiple subtypes present a challenge for the physician who encounters a patient with this condition. Thus, we propose that morphea be classified into the following five groups: plaque, generalized, bullous, linear, and deep. This classification, based on clinical morphologic findings, will simplify the diagnostic and therapeutic approach.
Morphea represents a wide variety of clinical entities that seen to be on the opposite end of the scleroderma spectrum from systemic sclerosis. The cutaneous lesions eventually evolve from a sclerotic stage to a nonindurated stage, and residual hypopigmentation or hyperpigmentation follows. The histologic pattern in patients with morphea is similar to that in patients with progressive systemic sclerosis. Although treatment is nonstandardized, hydroxychloroquine sulfate may be beneficial.
对硬斑病（局限性硬皮病）进行分类和描述。
对硬斑病及其亚型进行综述。
目前硬斑病的分类不完整且令人困惑。随着对疾病谱的认识不断发展，其多种亚型的争议性和复杂性给诊治此类患者的医生带来了挑战。因此，我们建议将硬斑病分为以下五组：斑块状、泛发性、大疱性、线状和深部。这种基于临床形态学表现的分类将简化诊断和治疗方法。
硬斑病代表了多种临床实体，似乎处于系统性硬化症硬皮病谱的另一端。皮肤病变最终从硬化阶段发展到非硬结阶段，并伴有残留的色素减退或色素沉着。硬斑病患者的组织学模式与进行性系统性硬化症患者相似。尽管治疗方法不规范，但硫酸羟氯喹可能有益。
